Trial reportAmerican journal of respiratory and critical care medicine2021
A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.
Open access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
9.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.The Cochrane database of systematic reviews · 2025Pooled it
- Stenotrophomonas maltophilia in people with Cystic Fibrosis: a systematic review of prevalence, risk factors and management.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Pooled it
- Correlates of FEV₁ deficit in pulmonary exacerbations of cystic fibrosis and associated clinical outcomes.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Trial
- An Observational Cohort Study of Targeted Antibiotic Treatments of Cystic Fibrosis Exacerbations.Open forum infectious diseases · 2026Trial
- Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial.The European respiratory journal · 2025Trial
- Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.Annals of the American Thoracic Society · 2024Trial
- Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.Annals of the American Thoracic Society · 2024Trial
- Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Trial
- Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Trial
- Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Trial
- Pulmonary Exacerbations and Treatment in PCD: A Narrative Review.Pediatric pulmonology · 2026Review
- Cystic Fibrosis Newborn Screening: Cost Trajectory as a Marker to Improve Health Outcomes.Pediatric pulmonology · 2026Article
- Risk factors for longitudinal estimated glomerular filtration rate decline in adults with cystic fibrosis.Annals of the American Thoracic Society · 2026Article
- Evaluating the association of antibiotic spectrum and treatment responses of cystic fibrosis pulmonary exacerbations.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Article
- Ecological partitioning enables phage-antibiotic cooperation in a human Pseudomonas infection.Nature communications · 2026Article
- PDE4 Inhibitor Apremilast Rebalances Inflammatory Responses to Pseudomonas aeruginosa Infection in CF Rats.bioRxiv : the preprint server for biology · 2026Article
- Hitting the Target: Model-Informed Precision Dosing of Tobramycin in Pediatric Patients with Cystic Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Airway Microbiome in Children with Cystic Fibrosis: A Review of Microbial Shifts and Therapeutic Impacts.Medicina (Kaunas, Lithuania) · 2025Review
- Screening and monitoring across the lifespan of an ageing cystic fibrosis population.ERJ open research · 2025Review
- Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 9 institutions in 1 country.
Christopher H GossDepartment of Medicine and.ORCID 0000-0001-8602-0309
Sonya L HeltsheDepartment of Pediatrics, University of Washington, Seattle, Washington.
Natalie E WestDepartment of Medicine, Johns Hopkins University, Baltimore, Maryland.
Michelle SkallandCF Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, Washington.
Don B SandersDepartment of Pediatrics, Indiana University, Indianapolis, Indiana.
Raksha JainDepartment of Medicine, University of Texas Southwestern, Dallas, Texas.
Tara L BartoDepartment of Medicine, Baylor College of Medicine, Houston, Texas.
Barbra FogartyCF Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, Washington.
Bruce C MarshallCystic Fibrosis Foundation, Bethesda, Maryland.
Donald R VanDevanterDepartment of Pediatrics, School of Medicine, Case Western Reserve University, Cleveland, Ohio; and.
Patrick A FlumeDepartment of Medicine and.
STOP2 Investigators
Seattle Children's Hospital · USUniversity of Washington · USBaylor College of Medicine · USCase Western Reserve University · USCystic Fibrosis Foundation · USIndiana University – Purdue University Indianapolis · USJohns Hopkins University · USMedical University of South Carolina · USThe University of Texas Southwestern Medical Center · US
Funding
South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1MTranslational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss · 2010 to 2026
$21.4MNCATS NIH HHS UL1 TR001450NIDDK NIH HHS P30 DK089507
Abstract
PubMed holds no abstract for this paper.
Indexed as
Disease ProgressionAdultAnti-Bacterial AgentsCystic FibrosisFemaleHumansMaleMiddle AgedRespiratory Function TestsRespiratory Tract InfectionsTime FactorsAnti-Bacterial Agentsclinical trialintravenous antibiotic therapyrespiratory infection
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.